Novo's (NOVOB DC) Ozempic for Australians is expected to fall from about AUD 300 a month for private patients to a small fraction after Australian patents expire in late 2029 and 2031, according to WA Today

The potential expiration of patents for Novo's Ozempic in Australia could significantly reduce patient costs, impacting the firm's pricing power and market share.

Newsquawk StaffPublished On the live feed at 5 more headlines followed before this page went public
Newsquawk headlinesUTC

Newsquawk Daily US Opening News - 13th April 2026

North Sea Forties crude oil reaches a record high of USD 148.87/bbl, according to LSEG data; supply concerns will be boosted by US plans to block the Strait

Novo's (NOVOB DC) Ozempic for Australians is expected to fall from about AUD 300 a month for private patients to a small fraction after Australian patents expire in late 2029 and 2031, according to WA Today

Amazon (AMZN) has quietly expanded its car sales business over the past year and a half, WSJ reports

New pharma tariffs are pushing biotech firms to consider voluntary pricing deals with the Trump administration for exemptions, Axios reports

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

This scenario may shape investor sentiment towards Novo Nordisk, with possible read-throughs on profitability and competitive dynamics in the diabetes treatment market. Traders should watch for shifts in valuation as these regulatory changes approach.

Related headlines

The whole workspace, free to try.

Try it free